Compare 8x8 Inc (EGHT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Zimmer Biomet Holdings Inc — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 54.3× 8x8 Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EGHT | ZBH | |
|---|---|---|
Market Cap | $311.98M | $16.95B |
Volume | 1,639,086 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $2.76 | $103.98 |
52-Week Low | $1.59 | $79.58 |
Typical Hold Time | 16 Days | 89 Days |
Enterprise Value | $578.90M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI product growth, while analysts maintain a mixed consensus with a $19.77 price target representing significant upside potential.
The stock presents a high-risk, high-reward opportunity with strong revenue growth potential but faces challenges from negative net income and high debt levels. Key catalysts include continued earnings outperformance and AI platform adoption, while risks involve execution challenges and competitive pressures in the communications software sector.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
